Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GAI-122, for treatment of ischemic neurological disorders
Subscribe to our email newsletter
AlphaRx and Gaia have provided latest updates on GAI-122, an investigational injectable nano-emulsion formulated with AlphaRx’s proprietary drug delivery technology. Gaia plans to initiate a clinical development program to
further study GAI-122, for an acute and unmet neurological indication.
GAI-122 offers significant and direct neuroprotection in both in-vitro and in-vivo ischemic conditions. Experimental evidence suggests that the neuroprotective action of GAI-122 is related to its’ active inhibition of apoptosis or cell death.
GAI-122 is in the final stage of formulation optimization, which is expected to be completed by the end of summer 2009. After that the company will start clinical trial materials manufacturing, said the company.
Earlier, in October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all the development costs.